Oncolytics Biotech (ONCY) Capital Expenditures (2009 - 2024)
Oncolytics Biotech (ONCY) posted quarterly Capital Expenditures of -$4295.1 for Q4 2024, down 94.91% year-over-year from -$84417.1 in Q1 2024, and up 81.69% quarter-over-quarter from -$23457.7 in Q3 2024.
Oncolytics Biotech (ONCY) Capital Expenditures (2009 - 2024) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Capital Expenditures for 16 consecutive years, with -$4295.1 the latest figure, recorded in Q4 2024.
- In Q4 2024, Capital Expenditures fell 94.91% year-over-year to -$4295.1; the TTM figure through Dec 2024 stood at -$175216.8 (down 2868.73% YoY), while the FY2025 annual figure was $6000.0, down 96.55% from the prior year.
- Capital Expenditures rose to -$4295.1 in Q4 2024 per ONCY's latest filing, from -$23457.7 in the prior quarter.
- Across five years, Capital Expenditures topped out at $394475.3 in Q4 2021 and bottomed at -$162566.3 in Q3 2021.
- Historically, Capital Expenditures has averaged -$1171.6 across 5 years, with a median of -$6900.7 in 2022.
- On a YoY basis, Capital Expenditures climbed as much as 168513.99% in 2021 and fell as far as 1292.6% in 2021.
- Oncolytics Biotech's Capital Expenditures stood at $233.95 in 2020, then soared by 168513.99% to $394475.3 in 2021, then sank by 99.81% to $736.7 in 2022, then tumbled by 399.12% to -$2203.6 in 2023, then tumbled by 94.91% to -$4295.1 in 2024.
- Business Quant data shows ONCY's Capital Expenditures at -$4295.1 in Q4 2024, -$23457.7 in Q3 2024, and -$113326.8 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -4,295.09 |
| Dec 31, 2024 | -4,295.09 |
| Sep 30, 2024 | -23,457.71 |
| Sep 30, 2024 | -23,457.71 |
| Jun 30, 2024 | -113,326.78 |
| Jun 30, 2024 | -113,326.78 |
| Mar 31, 2024 | -34,137.21 |
| Mar 31, 2024 | -34,137.21 |
| Dec 31, 2023 | -2,203.61 |
| Dec 31, 2023 | -2,203.61 |
| Mar 31, 2023 | -3,698.48 |
| Mar 31, 2023 | -3,698.48 |
| Dec 31, 2022 | 736.70 |
| Dec 31, 2022 | 736.70 |
| Sep 30, 2022 | -6,900.72 |
| Sep 30, 2022 | -6,900.72 |
| Jun 30, 2022 | -9,133.65 |
| Jun 30, 2022 | -9,133.65 |
| Mar 31, 2022 | -28,421.11 |
| Mar 31, 2022 | -28,421.11 |